Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. This decision follows consideration of ...

The drug is an injectable plasma-free C1-esterase inhibitor (C1-INH) proven to help treat HAE attacks, which are caused by having insufficient blood protein called C1-INH, or by having C1-INH that ...

If approved, garadicimab will slot into CSL's product line alongside two C1 esterase inhibitor medicines, namely Berinert which is administered by intravenous injection to treat HAE attacks ...

As with other drugs, Haegarda (C1 esterase inhibitor subcutaneous [human]) can cause side effects, such as injection site reaction and allergic reaction. If you can’t tolerate side effects of ...

Laryngeal attacks carry a risk of asphyxiation, making untreated events potentially fatal.1 Hereditary angioedema with reduced C1 esterase inhibitor (C1-INH) function (HAE-C1-INH) is the most common, ...

As European markets navigate the challenges of escalating trade tensions and economic uncertainties, investors are increasingly looking for opportunities that offer both potential growth and ...

HAE is a rare genetic condition characterised by a deficiency or dysfunction in the C1 esterase inhibitor protein, leading to uncontrolled activation of the kallikrein-kinin system and resulting ...

Lev's Cinryze (C1 esterase inhibitor) should receive a decision from the FDA in October. Three other firms are seeking US approval for HAE drugs aimed at the acute market—Dyax, of Cambridge ...

The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja ...